Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom....
+See More2025-06-28 10:39:00 Saturday ET
Former New York Times science author and Harvard psychologist Daniel Goleman explains why great mental focus serves as a vital mainstream driver of personal
2025-07-12 11:35:00 Saturday ET
Mitch Anthony explains why it is now more important for top sales leaders to apply social skills and emotional competences to fulfill customer needs, wants,
2019-08-26 11:30:00 Monday ET
Partisanship matters more than the socioeconomic influence of the rich and elite interest groups. This new trend emerges from the recent empirical analysis
2019-04-23 19:45:00 Tuesday ET
Income and wealth concentration follows the ebbs and flows of the business cycle in America. Economic inequality not only grows among people, but it also gr
2023-02-28 10:27:00 Tuesday ET
Basic income reforms can contribute to better health care, public infrastructure, education, technology, and residential protection. Philippe Van Parijs
2023-11-30 08:29:00 Thursday ET
In addition to the OECD bank-credit-card model and Chinese online payment platforms, the open-payments gateways of UPI in India and Pix in Brazil have adapt